Eventide Healthcare Life Fund Investor Sentiment

ETCHX Fund  USD 29.20  0.13  0.45%   
Slightly above 54% of Eventide Healthcare's investor base is interested to short. The analysis of overall sentiment of trading Eventide Healthcare Life mutual fund suggests that many investors are impartial at this time. Eventide Healthcare's investing sentiment can be driven by a variety of factors including economic data, Eventide Healthcare's earnings reports, geopolitical events, and overall market trends.
  
over a year ago at news.google.com         
EVENTIDE HEALTHCARE LIFE SCIENCES FUND CELEBRATES ... - Valdosta Daily Times
Google News at Macroaxis
a day ago at ndtv.com         
Collegium System Not Enough, Proper Probe Needed Harish Salve On Judge Cash Case
news
few days ago at gurufocus.com         
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
Gurufocus Stories at Macroaxis
over a week ago at www.macroaxis.com         
Disposition of 2255 shares by Scott Dreyer of Collegium Pharmaceutical at 30.0049 subject to Rule 16...
Macroaxis News
over a week ago at www.macroaxis.com         
Disposition of 10445 shares by Colleen Tupper of Collegium Pharmaceutical at 30.006 subject to Rule ...
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Collegium Pharmaceutical, Inc. EVP Shirley R. Kuhlmann Sells 26,067 Shares of Stock
news
over two weeks ago at ndtv.com         
Collegium Recommends Calcutta High Court Judges Elevation To Top Court
news
over two weeks ago at thelincolnianonline.com         
Collegium Pharmaceutical, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts
news
over two weeks ago at www.macroaxis.com         
Disposition of 9826 shares by Shirley Kuhlmann of Collegium Pharmaceutical at 30.52 subject to Rule ...
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Collegium Pharmaceutical Shares Gap Up After Better-Than-Expected Earnings
news
over two weeks ago at finance.yahoo.com         
Collegium Pharmaceutical Q4 Earnings Taking a Look at Key Metrics Versus Estimates
Yahoo News
over six months ago at seekingalpha.com         
Tectonic, AVROBIO complete merger, announce 130.7M private placement
seekingalpha News
over six months ago at news.google.com         
Gabelli Funds LLC Invests 467000 in AVROBIO, Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
AVROBIO, Inc. Short Interest Up 11.3 percent in May - MarketBeat
Google News at Macroaxis
over six months ago at investing.com         
Avrobio executive buys shares worth over 970k
Investing News at Macroaxis
over six months ago at investorplace.com         
Discretionary transaction by Leonard Braden Michael of tradable shares of AVROBIO subject to Rule 16...
sbwire news
over six months ago at news.google.com         
AVROBIO Options Chain Prices 2024 - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
AVROBIO Posts Quarterly Earnings Results - MarketBeat
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
AVROBIO, Inc. Short Interest Update
news
over a year ago at benzinga.com         
SHAREHOLDER UPDATE Halper Sadeh LLC Investigates AXNX, KAMN, JNPR, AVRO
benzinga news
over a year ago at news.google.com         
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates...
Google News at Macroaxis
few days ago at thelincolnianonline.com         
Supernus Pharmaceuticals Upgraded at StockNews.com
news
few days ago at zacks.com         
Down -20.07 percent in 4 Weeks, Heres Why Supernus Looks Ripe for a Turnaround
zacks News
over a week ago at finance.yahoo.com         
Acquisition by Jonathan Rubin of 1875 shares of Supernus Pharmaceuticals subject to Rule 16b-3
Yahoo News
over two weeks ago at finance.yahoo.com         
Disposition of 2625 shares by Frank Mottola of Supernus Pharmaceuticals subject to Rule 16b-3
Yahoo News
over two weeks ago at www.macroaxis.com         
Disposition of 577 shares by Jonathan Rubin of Supernus Pharmaceuticals at 33.05 subject to Rule 16b...
Macroaxis News
over two weeks ago at gurufocus.com         
Acquisition by Timothy Dec of 2000 shares of Supernus Pharmaceuticals subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Is Supernus Pharmaceuticals, Inc. the Best Small Cap Pharma Stocks to Buy Now?
Yahoo News
over three weeks ago at simplywall.st         
Supernus Pharmaceuticals Full Year 2024 Earnings Beats Expectations
Simply Wall St News at Macroaxis
over three weeks ago at gurufocus.com         
Supernus Pharmaceuticals Inc Announces Participation in TD Cowen Health Care Conference
Gurufocus Stories at Macroaxis
over three weeks ago at finance.yahoo.com         
Viatris Earnings What To Look For From VTRS
Yahoo News
a day ago at gurufocus.com         
Acquisition by John Leite of 11006 shares of Veracyte subject to Rule 16b-3
Gurufocus Stories at Macroaxis
few days ago at kalkinemedia.com         
How Is Veracyte Expanding Its Market in Genomic Testing?
news
over a week ago at zacks.com         
Veracyte Stock Surges 45.6 percent in a Year Whats Driving the Rally?
zacks News
over a week ago at simplywall.st         
Shareholders Can Be Confident That Veracytes Earnings Are High Quality
Simply Wall St News at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Marc Stapley of 90601 shares of Veracyte subject to Rule 16b-3
Macroaxis News
over two weeks ago at simplywall.st         
Veracyte, Inc. Looks Inexpensive After Falling 26 percent But Perhaps Not Attractive Enough
Simply Wall St News at Macroaxis
over two weeks ago at finance.yahoo.com         
Disposition of 7000 shares by Annie McGuire of Veracyte at 33.84 subject to Rule 16b-3
Yahoo News
over two weeks ago at thelincolnianonline.com         
Veracyte Price Target Raised to 49.00
news
over three weeks ago at thelincolnianonline.com         
Veracyte Announces Quarterly Earnings Results
news
over three weeks ago at finance.yahoo.com         
Veracyte Inc Q4 2024 Earnings Call Highlights Record Revenue Growth and Strategic ...
Yahoo News
a day ago at forbes.com         
Buy, Sell, Or Hold Alnylam Stock At 280?
Usa forbes News
few days ago at finance.yahoo.com         
Arbor raises 74M amid genetic medicines funding slump
Yahoo News
few days ago at finance.yahoo.com         
RNA Therapeutics Market is expected to generate a revenue of USD 22.37 Billion by 2032, Globally, at...
Yahoo News
over a week ago at finance.yahoo.com         
Alnylam Rallies 62 percent in a Year Can the Stock Maintain This Momentum?
Yahoo News
over a week ago at finance.yahoo.com         
Disposition of 2750 shares by Schulman Amy W of Alnylam Pharmaceuticals at 131.21 subject to Rule 16...
Yahoo News
over a week ago at finance.yahoo.com         
WearOptimo Introduces World-Class Advisory Board to Further Advance Microwearable Sensor Technology ...
Yahoo News
over a week ago at news.google.com         
Disposition of 1173 shares by Greenstreet Yvonne of Alnylam Pharmaceuticals at 243.36 subject to Rul...
Google News at Macroaxis
over two weeks ago at finance.yahoo.com         
Grove AI Awarded the SCOPE Participant Engagement Award for Its AI-Powered Digital Staff and Platfor...
Yahoo News
over two weeks ago at gurufocus.com         
Alnylam Pharmaceuticals Announces Retirement of Co-Founder Dr. Phillip A. Sharp
Gurufocus Stories at Macroaxis
over two weeks ago at benzinga.com         
1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
benzinga news
3 days ago at www.macroaxis.com         
Acquisition by Vittiglio Joseph of 50000 shares of Bluebird Bio subject to Rule 16b-3
Macroaxis News
over a week ago at prnewswire.com         
LINGO RELEASES SPACE-THEMED STEM KITS AS FOUNDER PREPARES FOR HISTORIC ALL-FEMALE BLUE ORIGIN FLIGHT
prnewswire News
over a week ago at finance.yahoo.com         
BMS to acquire longtime cell therapy partner 2seventy bio for 286m
Yahoo News
over two weeks ago at prnewswire.com         
BLUE CROSS BLUE SHIELD OF MASSACHUSETTS AND MASSCHALLENGE ANNOUNCE 2025 HEALTH EQUITY BUSINESS ACCEL...
prnewswire News
over two weeks ago at news.google.com         
bluebird bio stock slides for second day on buyout news - MSN
Google News at Macroaxis
over three weeks ago at zacks.com         
Biotech Stock Roundup BLUE Down on Update, News From GILD, TRDA
zacks News
over three weeks ago at seekingalpha.com         
bluebird bio stock on watch after MA deal
seekingalpha News
over three weeks ago at businesswire.com         
Shareholder Alert Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for it...
businesswire News
over a month ago at prnewswire.com         
BLUE CROSS BLUE SHIELD OF MASSACHUSETTS ENHANCES DIABETES SUPPORT FOR MEMBERS
prnewswire News
over a month ago at globenewswire.com         
Blue Point Brewing Announces 5th Annual Shakedown on Main Street Festival
Macroaxis News: globenewswire.com
a day ago at globenewswire.com         
Acquisition by Pfreundschuh Peter P. of 60000 shares of Voyager Therapeutics at 7.6 subject to Rule ...
Macroaxis News: globenewswire.com
over a week ago at www.macroaxis.com         
Acquisition by Sandrock Alfred of 145000 shares of Voyager Therapeutics subject to Rule 16b-3
Macroaxis News
over a week ago at thelincolnianonline.com         
Voyager Therapeutics Earns Overweight Rating from Cantor Fitzgerald
news
over a week ago at finance.yahoo.com         
Voyager Therapeutics Q4 Earnings Snapshot
Yahoo News
over a week ago at news.google.com         
Rhumbline Advisers Increases Stake in Voyager Therapeutics, Inc. - Defense World
Google News at Macroaxis
over two weeks ago at finance.yahoo.com         
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimers approach
Yahoo News
over two weeks ago at globenewswire.com         
Voyager Reports Positive Topline Data for Single Ascending Dose Trial of Anti-Tau Antibody VY7523 an...
Macroaxis News: globenewswire.com
over three weeks ago at globenewswire.com         
VOYAGER ALERT Bragar Eagel Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voy...
Macroaxis News: globenewswire.com
over three weeks ago at news.google.com         
Acquisition by Robin Swartz of 71250 shares of Voyager Therapeutics subject to Rule 16b-3
Google News at Macroaxis
over three weeks ago at businesswire.com         
Disposition of 3894 shares by Robin Swartz of Voyager Therapeutics at 4.25 subject to Rule 16b-3
businesswire News
over three weeks ago at gurufocus.com         
Stonepine Capital Management, LLC Acquires Significant Stake in Edesa Biotech Inc
Gurufocus Stories at Macroaxis
over a month ago at gurufocus.com         
Galapagos NV Earnings Call Highlights Strategic Shifts and Financial Resilience
Gurufocus Stories at Macroaxis
over a month ago at seekingalpha.com         
Galapagos projects 2026 pivotal trials for GLPG5101 following FDA clearance
seekingalpha News
over a month ago at finance.yahoo.com         
Galapagos Loses -21.19 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the Corner
Yahoo News
over a month ago at news.google.com         
Galapagos downgraded by Barclays, PT cut to 22 - Investing.com
Google News at Macroaxis
over two months ago at news.google.com         
Belgium stocks lower at close of trade BEL 20 down 1.58 percent - Investing.com
Google News at Macroaxis
over three months ago at gurufocus.com         
Galapagos NV Stock Surges Amid Strong Industry Performance
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
Stonepine Capital Management, LLC Increases Stake in Verastem Inc
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
Prosight Management, LP Expands Stake in ADC Therapeutics SA
Gurufocus Stories at Macroaxis
over three months ago at insidermonkey.com         
Galapagos NV Q3 2024 Earnings Call Transcript
insidermonkey News
a minute ago at thelincolnianonline.com         
AbbVie Inc. Shares Sold by Janney Montgomery Scott LLC
news
a minute ago at thelincolnianonline.com         
Silver Oak Securities Incorporated Boosts Holdings in AbbVie Inc.
news
2 days ago at benzinga.com         
AbbVie Options Trading A Deep Dive into Market Sentiment
benzinga news
3 days ago at thelincolnianonline.com         
AbbVie Inc. Shares Purchased by Horizon Investments LLC
news
few days ago at zacks.com         
Disposition of 14973 shares by Timothy Richmond of AbbVie at 210.66 subject to Rule 16b-3
zacks News
few days ago at benzinga.com         
AbbVies Elahere Cuts Death Risk By 32, Shows Consistent Survival Benefit In Long-Term Analysis For C...
benzinga news
few days ago at thefly.com         
AbbVie announces final analysis of Phase 3 MIRASOL trial ABBV
news
few days ago at finance.yahoo.com         
1 No-Brainer High-Yield Dividend ETF to Buy During the Stock Market Correction
Yahoo News
six days ago at finance.yahoo.com         
ELAHERE Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
Yahoo News
over a week ago at thelincolnianonline.com         
AbbVie Inc. Stock Holdings Lifted by Midwest Professional Planners LTD.
news
over a year ago at hawaiinewsnow.com         
Purchase by Sumitomo Chemical Co Ltd of 51599200 shares of Myovant Sciences
news
a day ago at finance.yahoo.com         
Hansa Biopharma publishes 2024 Annual and Sustainability Reports
Yahoo News
3 days ago at thelincolnianonline.com         
Thrivent Financial for Lutherans Buys 14,444 Shares of Sarepta Therapeutics, Inc.
news
few days ago at gurufocus.com         
SRPT Stock Drops Following Patient Death During Gene Therapy Trial
Gurufocus Stories at Macroaxis
few days ago at gurufocus.com         
Sarepta Therapeutics, Inc. Investors Company Investigated by the Portnoy Law Firm
Gurufocus Stories at Macroaxis
over a week ago at businesswire.com         
Disposition of 9746 shares by Nicaise Claude of Sarepta Therapeutics at 25.18 subject to Rule 16b-3
businesswire News
over a week ago at benzinga.com         
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney D...
benzinga news
over two weeks ago at thelincolnianonline.com         
Sarepta Therapeutics Reaches New 12-Month Low Whats Next?
news
over two weeks ago at simplywall.st         
Sarepta Therapeutics, Inc.s Low PS No Reason For Excitement
Simply Wall St News at Macroaxis
over two weeks ago at seekingalpha.com         
Sarepta Therapeutics files for potential mixed shelf offering
seekingalpha News
over two weeks ago at finance.yahoo.com         
Sarepta Therapeutics Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags
Yahoo News
over a year ago at thelincolnianonline.com         
Mirati Therapeutics Now Covered by Analysts at StockNews.com
news
over a year ago at finance.yahoo.com         
Billionaire Joe Lewis Pleads Guilty in Insider Trading Case
Yahoo News
over a year ago at smh.com.au         
Billionaire pleads guilty in insider trading case with a link to an Australian giant
news
over a year ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over a year ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over a year ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over a year ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over a year ago at aol.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
news
over a year ago at seekingalpha.com         
Mirati Therapeutics stock ticks higher amid Nasdaq delisting for sale to Bristol-Myers
seekingalpha News
over a year ago at thelincolnianonline.com         
Brokerages Set Mirati Therapeutics, Inc. PT at 60.00
news
a minute ago at gurufocus.com         
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
Gurufocus Stories at Macroaxis
over a week ago at businesswire.com         
908 Devices Receives 1.7M Order from the Ministry of Health of Ukraine for its Handheld Mass Spec De...
businesswire News
over two weeks ago at simplywall.st         
March 2025 Penny Stocks To Watch And Analyze
Simply Wall St News at Macroaxis
over two weeks ago at gurufocus.com         
908 Devices Inc Q4 2024 Earnings Call Highlights Strong Revenue Growth Amid Strategic ...
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
908 Devices Strategic Shift Desktop Sale To Repligen Optimizes Future Growth
Yahoo News
over two weeks ago at gurufocus.com         
908 Devices Inc Q4 2024 Earnings EPS Misses, Revenue Beats Estimates with 18.8 Million
Gurufocus Stories at Macroaxis
over two weeks ago at businesswire.com         
Acquisition by Turner Michael S. of 57111 shares of 908 Devices at 1.98 subject to Rule 16b-3
businesswire News
over three weeks ago at zacks.com         
Teleflex Surpasses Q4 Earnings Estimates
zacks News
over three weeks ago at thelincolnianonline.com         
908 Devices to Release Earnings on Tuesday
news
over a month ago at newswire.com         
MASS Group Unveils TME 8.0 A Modernized Interface for Enhanced User Experience and Operational Perfo...
news
a minute ago at finance.yahoo.com         
Neurocrines Phase II schizophrenia trial fails to meet primary endpoint
Yahoo News
2 days ago at finance.yahoo.com         
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGRE...
Yahoo News
few days ago at finance.yahoo.com         
Neurocrine Biosciences Presents New KINECT-HD Data Showing Significant Reduction in Chorea Across Bo...
Yahoo News
over a week ago at www.macroaxis.com         
Acquisition by Roberts Eiry of 1860 shares of Neurocrine Biosciences subject to Rule 16b-3
Macroaxis News
over a week ago at thelincolnianonline.com         
Edgestream Partners L.P. Grows Stock Position in Neurocrine Biosciences, Inc.
news
over a week ago at thelincolnianonline.com         
Andra AP fonden Sells 77,600 Shares of Neurocrine Biosciences, Inc.
news
over two weeks ago at finance.yahoo.com         
Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults
Yahoo News
over two weeks ago at finance.yahoo.com         
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Seco...
Yahoo News
over two weeks ago at benzinga.com         
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study...
benzinga news
over three weeks ago at finance.yahoo.com         
Xenon Reports Fourth Quarter Full Year 2024 Financial Results and Business Update
Yahoo News
a day ago at www.macroaxis.com         
Insider Trading
Macroaxis News
few days ago at globenewswire.com         
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg for the Treatment of Walden...
Macroaxis News: globenewswire.com
few days ago at gurufocus.com         
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexo
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D. ...
Gurufocus Stories at Macroaxis
over a week ago at zacks.com         
Acquisition by Baynes Roy D. of 50000 shares of Nurix Therapeutics at 13.9 subject to Rule 16b-3
zacks News
over two weeks ago at thelincolnianonline.com         
Nurix Therapeutics, Inc. CFO Sells 84,404.25 in Stock
news
over two weeks ago at gurufocus.com         
Nurix Therapeutics Inc Announces Participation in Key March Conferences
Gurufocus Stories at Macroaxis
over three weeks ago at news.google.com         
ARK Investment Management LLC Sells 686,072 Shares of Nurix Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
over a month ago at gurufocus.com         
Nurix Therapeutics Inc Announces Inducement Awards to New Employees
Gurufocus Stories at Macroaxis
over a year ago at news.google.com         
Global markets live Adobe, Eli Lilly, Nasdaq, Intel, UBS... - Marketscreener.com
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
Boxer Capital LLC Boosts Stock Position in Prometheus Biosciences, Inc.
news
over a year ago at www.macroaxis.com         
Exercise or conversion by Mark McKenna of 122528 shares of Prometheus Biosciences subject to Rule 16...
Macroaxis News
over a year ago at news.google.com         
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, L...
Google News at Macroaxis
over a year ago at simplywall.st         
We Think Prometheus Biosciences Can Afford To Drive Business Growth
Simply Wall St News at Macroaxis
over a year ago at zacks.com         
Prometheus Biosciences, Inc. is a Great Momentum Stock Should You Buy?
zacks News
over a year ago at zacks.com         
Prometheus Biosciences, Inc. Reports Q1 Loss, Tops Revenue Estimates
zacks News
over a year ago at news.google.com         
Ieq Capital LLC Sells off 35.3 percent of Holding in Prometheus ... - Best Stocks
Google News at Macroaxis
over a year ago at news.google.com         
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors - Marketscre...
Google News at Macroaxis
over a year ago at fool.com         
Why Madrigal Pharmaceuticals Stock Gained 20 percent This Week
fool News
over six months ago at www.macroaxis.com         
Disposition of 8500 shares by Jonas Jeffrey M of Karuna Therapeutics at 128.01 subject to Rule 16b-3
Macroaxis News
over six months ago at bizjournals.com         
PureTechs newest biotech spinout represents a shift from the past
bizjournals News
over a year ago at news.google.com         
Disposition of 17350 shares by Stephen Brannan of Karuna Therapeutics at 187.26 subject to Rule 16b-...
Google News at Macroaxis
over a year ago at simplywall.st         
When Will Karuna Therapeutics, Inc. Turn A Profit?
Simply Wall St News at Macroaxis
over a year ago at news.google.com         
Karuna Therapeutics, Inc. Receives Consensus Recommendation of Hold from Analysts - Defense World
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics Short Position
Yahoo News
over a year ago at www.macroaxis.com         
Acquisition by Steven Paul of 47378 shares of Karuna Therapeutics at 315.18 subject to Rule 16b-3
Macroaxis News
over a year ago at seekingalpha.com         
Karuna Therapeutics stock drops on no apparent news amid deal with Bristol-Myers Squibb
seekingalpha News
over a year ago at thelincolnianonline.com         
Algert Global LLC Has 3.12 Million Stock Holdings in Karuna Therapeutics, Inc.
news
over a year ago at zacks.com         
Acquisition by Steven Paul of 27510 shares of Karuna Therapeutics at 7.27 subject to Rule 16b-3
zacks News
few days ago at news.google.com         
Sutro Biopharma lays off dozens of employees in strategic portfolio review - Yahoo News
Google News at Macroaxis
six days ago at simplywall.st         
Sutro Biopharma Full Year 2024 Earnings Revenues Beat Expectations, EPS Lags
Simply Wall St News at Macroaxis
over a week ago at gurufocus.com         
Sutro Biopharma Inc Q4 2024 Earnings Call Highlights Strategic Focus and Financial ...
Gurufocus Stories at Macroaxis
over a week ago at zacks.com         
Sutro Biopharma, Inc. Reports Q4 Loss, Tops Revenue Estimates
zacks News
over two weeks ago at www.macroaxis.com         
Disposition of 6708 shares by Newell William J of Sutro Biopharma at 1.36 subject to Rule 16b-3
Macroaxis News
over two weeks ago at simplywall.st         
Sutro Biopharma, Inc. Not Doing Enough For Some Investors As Its Shares Slump 25
Simply Wall St News at Macroaxis
over two weeks ago at aol.com         
Man jailed again for breaching city centre ban
news
over a month ago at news.google.com         
Sutro Biopharma stock hits 52-week low at 1.67 amid market challenges - Investing.com
Google News at Macroaxis
over two months ago at news.google.com         
Brokerages Set Sutro Biopharma, Inc. Target Price at 11.13 - MarketBeat
Google News at Macroaxis
over two months ago at gurufocus.com         
Sutro Biopharma and Boehringer Ingelheim BioXcellence collabora
Gurufocus Stories at Macroaxis
a day ago at kalkinemedia.com         
Is Xencor Gaining Momentum Through Institutional Activity and Financial Results?
news
few days ago at www.macroaxis.com         
Disposition of 13301 shares by Montgomery Alan Bruce of Xencor at 27.0299 subject to Rule 16b-3
Macroaxis News
over a week ago at news.google.com         
Mutual of America Capital Management LLC Buys Shares of 10,600 Xencor, Inc. - Defense World
Google News at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Bart Cornelissen of 65847 shares of Xencor at 14.15 subject to Rule 16b-3
Macroaxis News
over two weeks ago at www.macroaxis.com         
Acquisition by Montgomery Alan Bruce of 10013 shares of Xencor at 26.19 subject to Rule 16b-3
Macroaxis News
over two weeks ago at simplywall.st         
Xencor Full Year 2024 Earnings Beats Expectations
Simply Wall St News at Macroaxis
over two weeks ago at kalkinemedia.com         
Why Are Institutional Investors Adjusting Their Positions in Xencor Inc.?
news
over three weeks ago at gurufocus.com         
Xencor Inc Reports 2024 Financial Results and Outlines 2025 Clinical Priorities
Gurufocus Stories at Macroaxis
over three weeks ago at www.macroaxis.com         
Disposition of 68684 shares by John Desjarlais of Xencor at 15.69 subject to Rule 16b-3
Macroaxis News
over three weeks ago at zacks.com         
Ardelyx Meets Q4 Earnings Estimates
zacks News
few days ago at news.google.com         
Allakos Inc. Hold Rating Amid Restructuring and Financial Uncertainty - TipRanks
Google News at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 31370 shares by Robert Alexander of Allakos at 0.26 subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reve...
Yahoo News
over a month ago at thelincolnianonline.com         
Piper Sandler Downgrades Allakos to Hold
news
over a month ago at gurufocus.com         
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic ...
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
Discover US Penny Stocks To Watch In January 2025 - Yahoo Finance
Google News at Macroaxis
over three months ago at news.google.com         
Point72 Asset Management L.P. Purchases New Position in Allakos Inc. - MarketBeat
Google News at Macroaxis
over three months ago at www.macroaxis.com         
Disposition of 32466 shares by Robert Alexander of Allakos at 1.1 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Allakos Inc. finalizes early lease termination, incurring 2.5 million in costs - Investing.com
Google News at Macroaxis
over three months ago at zacks.com         
All You Need to Know About Allakos Rating Upgrade to Buy
zacks News
a day ago at thelincolnianonline.com         
iA Global Asset Management Inc. Purchases 270 Shares of argenx SE
news
few days ago at zacks.com         
Argenx Surges 4.1 percent Is This an Indication of Further Gains?
zacks News
over a week ago at finance.yahoo.com         
Artisan Small Cap Fund Sold argenx SE as it Exceeded Small-Cap Mandate
Yahoo News
over two weeks ago at thelincolnianonline.com         
Wedbush Comments on argenxs Q2 Earnings
news
over two weeks ago at thelincolnianonline.com         
Robert W. Baird Forecasts Strong Price Appreciation for argenx Stock
news
over two weeks ago at insidermonkey.com         
argenx SE Q4 2024 Earnings Call Transcript
insidermonkey News
over three weeks ago at gurufocus.com         
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
Gurufocus Stories at Macroaxis
over three weeks ago at zacks.com         
Jazz Stock Gains as Q4 Earnings Sales Surpass Expectations
zacks News
over three weeks ago at gurufocus.com         
argenx SE to Present at TD Cowen 45th Annual Healthcare Conference
Gurufocus Stories at Macroaxis
over three weeks ago at zacks.com         
SpringWorks Q4 Loss Wider Than Expected, Revenues Beat Estimates
zacks News
a day ago at news.google.com         
Biotech designed to commercialize Ascendis endocrinology drugs in China files 86M IPO - FiercePharma
Google News at Macroaxis
few days ago at finance.yahoo.com         
Ascendis Pharma Soars 10.4 percent Is Further Upside Left in the Stock?
Yahoo News
over a week ago at news.google.com         
Ascendis Pharma Grants Employee Warrants to Strengthen Retention - TipRanks
Google News at Macroaxis
over two weeks ago at gurufocus.com         
Avoro Capital Advisors LLC Increases Stake in Aadi Bioscience Inc
Gurufocus Stories at Macroaxis
over three weeks ago at thelincolnianonline.com         
Ascendis Pharma AS Shares Sold by Handelsbanken Fonder AB
news
over three weeks ago at gurufocus.com         
Ascendis Pharma to Participate in theTD Cowen 45th Annual Healt
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Q1 EPS Forecast for Ascendis Pharma AS Decreased by Analyst
news
over a month ago at finance.yahoo.com         
High Growth Tech Stocks And 2 More High Potential Picks
Yahoo News
over a month ago at finance.yahoo.com         
Ascendis Pharma AS Just Reported Annual Earnings Have Analysts Changed Their Mind On The Stock?
Yahoo News
over a month ago at gurufocus.com         
JANUS HENDERSON GROUP PLC Expands Stake in Ascendis Pharma AS
Gurufocus Stories at Macroaxis
few days ago at kalkinemedia.com         
How Is Biohaven Ltd. Supporting Its Clinical Trials?
news
over a week ago at news.google.com         
Biohaven Ltd. Shares Bought by Bank of New York Mellon Corp - Defense World
Google News at Macroaxis
over a week ago at finance.yahoo.com         
Biohaven Ltd. Among Stocks with Heavy Insider Buying in 2025
Yahoo News
over two weeks ago at kalkinemedia.com         
How Biohaven Ltd. Is Advancing Treatments for Complex Disorders
news
over two weeks ago at gurufocus.com         
INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
Gurufocus Stories at Macroaxis
over two weeks ago at thelincolnianonline.com         
Biohaven Ltd. Director Purchases 996,369.00 in Stock
news
over two weeks ago at gurufocus.com         
Beyond the Balance Sheet What SWOT Reveals About Biohaven Ltd
Gurufocus Stories at Macroaxis
over two weeks ago at thelincolnianonline.com         
Acquisition by John Childs of 3400 shares of Biohaven Pharmaceutical at 30.7261 subject to Rule 16b-...
news
over two weeks ago at gurufocus.com         
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial ...
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Biohaven Ltd Announces FDA Priority Review and Financial Results
Gurufocus Stories at Macroaxis
a minute ago at benzinga.com         
IonQ, HE Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week Are The Others I...
benzinga news
3 days ago at kalkinemedia.com         
Is Blueprint Medicines Gaining Momentum in the Biotechnology Sector?
news
over a week ago at news.google.com         
Disposition of 1800 shares by Albers Jeffrey W. of Blueprint Medicines at 88.37 subject to Rule 16b-...
Google News at Macroaxis
over a week ago at news.google.com         
Blueprint Medicines Co. Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
Google News at Macroaxis
over two weeks ago at simplywall.st         
Is Blueprint Medicines A Risky Investment?
Simply Wall St News at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 2541 shares by Hewes L. Becker of Blueprint Medicines at 87.98 subject to Rule 16b-3
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Fisher Asset Management LLC Sells 12,310 Shares of Blueprint Medicines Co.
news
over two weeks ago at www.macroaxis.com         
Acquisition by Durso-bumpus Debra of 22000 shares of Blueprint Medicines at 96.57 subject to Rule 16...
Macroaxis News
over three weeks ago at zacks.com         
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
zacks News
over three weeks ago at www.macroaxis.com         
Disposition of 400 shares by Haviland Kate of Blueprint Medicines at 95.4 subject to Rule 16b-3
Macroaxis News
2 days ago at cnbc.com         
Here are Thursdays biggest analyst calls Nvidia, Tesla, Boeing, Microsoft, Cava, Boston Beer, Amazon...
cnbc News
over two weeks ago at finance.yahoo.com         
Atopic Dermatitis 2025 Pipeline Insights Report Covering 100 Companies and 120 Pipeline Drugs, Inclu...
Yahoo News
over two weeks ago at globenewswire.com         
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Progra...
Macroaxis News: globenewswire.com
over two weeks ago at thelincolnianonline.com         
Celldex Therapeutics Reaches New 52-Week Low Following Analyst Downgrade
news
over two weeks ago at simplywall.st         
Celldex Therapeutics Full Year 2024 Earnings Revenues Beat Expectations, EPS In Line
Simply Wall St News at Macroaxis
over two weeks ago at gurufocus.com         
Celldex Therapeutics Inc Reports Positive Phase 2 Results for Barzolvolimab in Chronic ...
Gurufocus Stories at Macroaxis
over three weeks ago at finance.yahoo.com         
Celldex Q4 Earnings Snapshot
Yahoo News
over three weeks ago at gurufocus.com         
Celldex Therapeutics Q4 2024 Earnings EPS Matches Estimates at 0. ...
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Elizabeth Crowley of 85000 shares of Celldex Therapeutics at 36.43 subject to Rule 16...
Macroaxis News
over a month ago at thelincolnianonline.com         
TSP Capital Management Group LLC Has 5.64 Million Holdings in Celldex Therapeutics, Inc.
news
2 days ago at zacks.com         
Is Cogent Biosciences Stock a Solid Choice Right Now?
zacks News
over a week ago at news.google.com         
Scotiabank Initiates Coverage of Cogent Biosciences with Sector Outperform Recommendation - Nasdaq
Google News at Macroaxis
over two weeks ago at news.google.com         
When the Price of Talks, People Listen - Stock Traders Daily
Google News at Macroaxis
over three weeks ago at globenewswire.com         
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financia...
Macroaxis News: globenewswire.com
over three weeks ago at news.google.com         
Long Term Trading Analysis for - Stock Traders Daily
Google News at Macroaxis
over a month ago at gurufocus.com         
FMR LLCs Strategic Acquisition of Cogent Biosciences Shares
Gurufocus Stories at Macroaxis
over a month ago at gurufocus.com         
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis ...
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Cogent Biosciences, Inc. Short Interest Update
news
over a month ago at gurufocus.com         
Cogent Biosciences Inc Announces Participation in Guggenheim SMID Cap Biotech Conference
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Kearns Evan of 230000 shares of Cogent Biosciences at 8.89 subject to Rule 16b-3
Macroaxis News
a day ago at zacks.com         
Exact Sciences Down 10.6 percent Since Last Earnings Report Can It Rebound?
zacks News
3 days ago at simplywall.st         
Exact Sciences Is Carrying A Fair Bit Of Debt
Simply Wall St News at Macroaxis
over a week ago at thelincolnianonline.com         
Postrock Partners LLC Purchases New Stake in Exact Sciences Co.
news
over a week ago at gurufocus.com         
Exact Sciences Corp Shares Down 7.9 percent on Mar 13
Gurufocus Stories at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 66723 shares by Kevin Conroy of EXACT Sciences at 22.38 subject to Rule 16b-3
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Grandfield Dodd LLC Purchases 4,962 Shares of Exact Sciences Co.
news
over two weeks ago at finance.yahoo.com         
Disposition of 1055 shares by Sarah Condella of EXACT Sciences subject to Rule 16b-3
Yahoo News
over two weeks ago at thelincolnianonline.com         
Disposition of 3780 shares by Sarah Condella of EXACT Sciences subject to Rule 16b-3
news
over three weeks ago at www.macroaxis.com         
Disposition of 54 shares by Orville Jacob A of EXACT Sciences subject to Rule 16b-3
Macroaxis News
over three weeks ago at gurufocus.com         
Disposition of 13180 shares by Kevin Conroy of EXACT Sciences subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Montara Therapeutics Closes 20M Oversubscribed Seed Expansion, Appoints Troy Wilson as Chairman of t...
Yahoo News
over two weeks ago at globenewswire.com         
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635
Macroaxis News: globenewswire.com
over two weeks ago at news.google.com         
UBS Adjusts Price Target on Kura Oncology to 14 From 27, Keeps Buy Rating -March 06, 2025 at 0952 am...
Google News at Macroaxis
over two weeks ago at thelincolnianonline.com         
Research Analysts Set Expectations for Kura Oncology Q1 Earnings
news
over three weeks ago at gurufocus.com         
Kura Oncology Inc Q4 2024 Earnings Call Highlights Strategic Advances and Financial Growth
Gurufocus Stories at Macroaxis
over three weeks ago at seekingalpha.com         
Kura Oncology GAAP EPS of -0.22 misses by 0.18, revenue of 53.88M misses by 4.08M
seekingalpha News
over three weeks ago at gurufocus.com         
Kura Oncology Inc Q4 2024 Earnings EPS of -0.22 Beats Estimate, Revenue Soars to 53. ...
Gurufocus Stories at Macroaxis
over three weeks ago at seekingalpha.com         
Kura Oncology Q4 2024 Earnings Preview
seekingalpha News
over a month ago at gurufocus.com         
Suvretta Capital Management, LLC Reduces Stake in Erasca Inc
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
Wedbush Forecasts Strong Price Appreciation for Kura Oncology Stock
news
a minute ago at finance.yahoo.com         
Heres What Key Metrics Tell Us About Vertex Q4 Earnings
Yahoo News
2 days ago at finance.yahoo.com         
Crunchbase Hires Ann Davis as Senior Vice President of Sales to Scale AI-Powered Market Intelligence
Yahoo News
3 days ago at zacks.com         
Vertex Pharmaceuticals Rises But Trails Market What Investors Should Know
zacks News
few days ago at finance.yahoo.com         
NVIDIA Announces Major Release of Cosmos World Foundation Models and Physical AI Data Tools
Yahoo News
few days ago at finance.yahoo.com         
2 No-Brainer Artificial Intelligence Stocks to Buy in March
Yahoo News
few days ago at aol.com         
UK must have global ambition in AI, DeepMinds Hassabis says
news
over a week ago at finance.yahoo.com         
Why Is Alkermes Down 6.6 percent Since Last Earnings Report?
Yahoo News
over a week ago at zacks.com         
Disposition of 3231 shares by Altshuler David of Vertex Pharmaceuticals at 510.0 subject to Rule 16b...
zacks News
over a week ago at benzinga.com         
A Closer Look at Vertex Pharmaceuticalss Options Market Dynamics
benzinga news
over a week ago at statnews.com         
STAT In the Boston area, biotechs hub, a slump is being acutely felt
news
a day ago at news.google.com         
Technical Pivots with Risk Controls - Stock Traders Daily
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by Benjamin Palleiko of 30195 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over a week ago at news.google.com         
KALVISTA PHARMACEUTICALS Earnings Results KALV Reports Quarterly Earnings - Nasdaq
Google News at Macroaxis
over two weeks ago at www.macroaxis.com         
Disposition of 6669 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 11.97 subject to Rule...
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Brokerages Set KalVista Pharmaceuticals, Inc. PT at 23.80
news
over two weeks ago at finance.yahoo.com         
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Ast...
Yahoo News
over three weeks ago at thelincolnianonline.com         
KalVista Pharmaceuticals, Inc. Insider Paul K. Audhya Sells 2,394 Shares of Stock
news
over three weeks ago at thelincolnianonline.com         
KalVista Pharmaceuticals, Inc. CEO Sells 50,121.28 in Stock
news
over three weeks ago at businesswire.com         
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma...
businesswire News
over three weeks ago at businesswire.com         
Acquisition by Brian Piekos of 80000 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
businesswire News
a day ago at kalkinemedia.com         
How Does AnaptysBio Fit Into the Broader Biotech Landscape?
news
3 days ago at www.macroaxis.com         
Disposition of 5000 shares by Eric Loumeau of AnaptysBio at 14.02 subject to Rule 16b-3
Macroaxis News
six days ago at news.google.com         
Wells Fargo Predicts Up to 440 percent Rally for These 2 Strong Buy Stocks - Markets Insider
Google News at Macroaxis
over a week ago at news.google.com         
HC Wainwright Reaffirms Neutral Rating for AnaptysBio - MarketBeat
Google News at Macroaxis
over two weeks ago at thelincolnianonline.com         
AnaptysBio, Inc. Short Interest Up 54.4 percent in February
news
over two weeks ago at thelincolnianonline.com         
AnaptysBio Shares Gap Up on Better-Than-Expected Earnings
news
over three weeks ago at seekingalpha.com         
AnaptysBio GAAP EPS of -0.72 beats by 0.91, revenue of 43.11M
seekingalpha News
over three weeks ago at gurufocus.com         
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Gurufocus Stories at Macroaxis
over a month ago at simplywall.st         
AnaptysBio, Inc. Stock Rockets 29 percent As Investors Are Less Pessimistic Than Expected
Simply Wall St News at Macroaxis
over a month ago at finance.yahoo.com         
AnaptysBio Surges 30.5 percent Is This an Indication of Further Gains?
Yahoo News
2 days ago at thelincolnianonline.com         
Twin Tree Management LP Takes Position in uniQure
news
few days ago at thelincolnianonline.com         
Disposition of 10438 shares by Christian Klemt of Uniqure NV at 10.29 subject to Rule 16b-3
news
over a week ago at www.macroaxis.com         
Disposition of 6717 shares by Matthew Kapusta of Uniqure NV at 11.32 subject to Rule 16b-3
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Acquisition by Abi-saab Walid of 66000 shares of Uniqure NV at 10.9 subject to Rule 16b-3
news
over two weeks ago at www.macroaxis.com         
Disposition of 7076 shares by Potts Jeannette of Uniqure NV at 10.29 subject to Rule 16b-3
Macroaxis News
over two weeks ago at simplywall.st         
Dont Ignore The Insider Selling In uniQure
Simply Wall St News at Macroaxis
over two weeks ago at thelincolnianonline.com         
uniQure Price Target Lowered to 30.00 at Wells Fargo Company
news
over three weeks ago at seekingalpha.com         
uniQure GAAP EPS of -4.92 misses by 0.97, revenue of 27.1M misses by 12.3M
seekingalpha News
over three weeks ago at www.macroaxis.com         
Acquisition by Christian Klemt of 5712 shares of Uniqure NV subject to Rule 16b-3
Macroaxis News
over three weeks ago at thelincolnianonline.com         
Acquisition by Jacques Rachelle Suzanne of 8080 shares of Uniqure NV subject to Rule 16b-3
news
few days ago at thelincolnianonline.com         
Picton Mahoney Asset Management Has 35,000 Holdings in Sage Therapeutics, Inc.
news
over a week ago at zacks.com         
Can BIIBs New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
zacks News
over two weeks ago at gurufocus.com         
FMR LLC Reduces Stake in Sage Therapeutics Inc A Strategic Portfolio Adjustment
Gurufocus Stories at Macroaxis
over two weeks ago at businesswire.com         
Sage Therapeutics Announces RD Leadership Transition
businesswire News
over two weeks ago at finance.yahoo.com         
Sage Geosystems Achieves Awardable Status by the U.S. Department of Defense for the U.S. Air Force G...
Yahoo News
over three weeks ago at finance.yahoo.com         
Is Sage Therapeutics, Inc. the Best Small-Cap Growth Stock to Buy Now?
Yahoo News
over a month ago at thelincolnianonline.com         
Q1 EPS Forecast for Sage Therapeutics Boosted by Analyst
news
over a month ago at gurufocus.com         
RTW INVESTMENTS, LP Reduces Stake in Sage Therapeutics Inc
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
Sage debuts new conference experience in Atlanta for SMBs Sage Future
Yahoo News
over a month ago at aol.com         
Can your EV really power your home Heres how your car battery does more than you think
news
Far too much social signal, news, headlines, and media speculation about Eventide Healthcare that are available to investors today. That information is available publicly through Eventide media outlets and privately through word of mouth or via Eventide internal channels. However, regardless of the origin, that massive amount of Eventide data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eventide Healthcare news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eventide Healthcare relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eventide Healthcare's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eventide Healthcare alpha.

Other Information on Investing in Eventide Mutual Fund

Eventide Healthcare financial ratios help investors to determine whether Eventide Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eventide with respect to the benefits of owning Eventide Healthcare security.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Global Correlations
Find global opportunities by holding instruments from different markets
Stocks Directory
Find actively traded stocks across global markets